Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595123 | 0.80 | KIF11 (0.38) | BRD4 | |
| SCHEMBL4596438 | 0.80 | KIF11 (0.38) | BRD4 | |
| Trifluoroacetic Acid SCHEMBL4799215 | 0.76 | PARP1 (0.51) | PARP1TSHRALDH1A1HPGDTP53 | |
| Trifluoroacetic Acid SCHEMBL4800639 | 0.76 | PARP1 (0.51) | PARP1TSHRALDH1A1HPGDTP53 | |
| SCHEMBL4801273 | 0.72 | HSD17B10 (0.44) | TSHRALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL5886628 | 0.72 | HSD17B10 (0.44) | TSHRALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL4799230 | 0.71 | HSD17B10 (0.46) | PARP1TSHRALDH1A1HPGDTP53 | |
| SCHEMBL4800646 | 0.71 | HSD17B10 (0.46) | PARP1TSHRALDH1A1HPGDTP53 | |
| SCHEMBL1562440 | 0.69 | PARP1 (0.65) | PARP1TSHRALDH1A1HPGDTP53 | |
| SCHEMBL1562544 | 0.69 | PARP1 (0.65) | PARP1TSHRALDH1A1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425550-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2008-09-16 | — | — | US | disclosed |
| US-7098235-B2 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | SHER PHILIP | 2006-06-15 | — | — | US | disclosed |
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | PYGL, PNLIP, PYGM | PARP1 1060/4885TSHR 2095/4885ALDH1A1 2808/4885 |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS1 | PARP1 1629/4885TSHR 1159/4885ALDH1A1 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.